Prescribing Adrenaline Auto-Injectors
The British Society for Allergy & Clinical Immunology (BSACI) provides detailed guidance on the appropriate prescription of adrenaline auto-injectors (AAIs) for patients at risk of anaphylaxis. These guidelines stress the importance of ensuring that patients have access to two AAIs at all times, given the potential need for a second dose in severe reactions.
Healthcare professionals are encouraged to assess the risk of anaphylaxis carefully and prescribe AAIs accordingly. The document highlights key factors to consider, including the patient’s history of allergic reactions, the likelihood of exposure to known allergens, and the severity of previous anaphylactic episodes.
Patient Education and Training
The guidelines also underline the crucial role of patient education. Healthcare providers should ensure that patients, as well as their families and carers, are thoroughly trained in recognising the early signs of anaphylaxis and the correct use of AAIs. This includes demonstrating how to administer the auto-injector, understanding when to use it, and ensuring that the patient knows to seek emergency medical help immediately after administering adrenaline.
Additionally, the guidelines recommend regular reviews of patients who are prescribed AAIs. These reviews should assess the continued need for AAIs, provide updates on their use, and ensure that patients remain confident in managing their condition. Patients should also be advised to carry their AAIs at all times and to check their devices regularly for expiry dates.
Importance of Comprehensive Documentation
Comprehensive documentation in the patient’s medical records is vital. This includes recording the rationale for prescribing AAIs, details of any training provided, and instructions given to the patient regarding follow-up and emergency care. This thorough documentation helps ensure continuity of care and aids in the ongoing management of patients at risk of anaphylaxis.
